SCHEMBL5578780

SCHEMBL5578780

[PbH]n1cnc2cncnc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.42
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
LTA4H P09960 1/20 0.36
CYP1A2 P05177 12/20 0.36
CYP3A4 P08684 9/20 0.36
ALDH1A1 P00352 8/20 0.36
CYP2C19 P33261 7/20 0.36
TSHR P16473 7/20 0.36
CYP2C9 P11712 7/20 0.36
LMNA P02545 4/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
HBB P68871 1/20 0.36
MKNK2 Q9HBH9 1/20 0.35
USP2 O75604 6/20 0.34
CLK4 Q9HAZ1 4/20 0.33
CYP2D6 P10635 2/20 0.33
HSD17B10 Q99714 3/20 0.32
MAPK1 P28482 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28340215 0.76 FDPS (0.44) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL27992403 0.74 FDPS (0.42) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL27689438 0.74 FDPS (0.42) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL30341176 0.74 GRM5 (0.46) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL256372 0.74 GRM5 (0.46) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL28763050 0.74 FDPS (0.46) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL28779724 0.74 FDPS (0.42) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL840562 0.74 FDPS (0.46) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL5633 0.74 FDPS (0.42) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL7787139 0.74 FDPS (0.42) FDPSHDAC1HDAC6LTA4HCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118355914-A Use of purine compounds for controlling pathogenic microorganisms 兰州大学 2024-07-19 CN disclosed
US-20070207512-A1 STRUCTURE-BASED DRUG DESIGN METHODS FOR IDENTIFYING D-ALA-D-ALA LIGASE INHIBITORS AS ANTIBACTERIAL DRUGS PLIVA D.D. (HR) 2007-09-06 US disclosed
CN-1268765-C Structure-based drug design methods for idenfitying D-ALA-D-ALA ligase inhibitors as antibacterial drugs ESSENTIAL THERAPEUTICS INC (US) 2006-08-09 CN disclosed
CN-1539020-A Structure-based drug design methods for idenfitying D-ALA-D-ALA ligase inhibitors as antibacterial drugs ��������ҽѧ���޹�˾ 2004-10-20 CN disclosed
EP-1412516-A4 STRUCTURE-BASED DRUG DESIGN METHODS FOR IDENTIFYING D-ALA-D-ALA LIGASE INHIBITORS AS ANTIBACTERIAL DRUGS ESSENTIAL THERAPEUTICS INC (US) 2004-09-08 EP disclosed
EP-1412516-A2 STRUCTURE-BASED DRUG DESIGN METHODS FOR IDENTIFYING D-ALA-D-ALA LIGASE INHIBITORS AS ANTIBACTERIAL DRUGS Essential Therapeutics, Inc. (US) 2004-04-28 EP disclosed
US-20030119061-A1 Structure-based drug design methods for identifying D-Ala-D-Ala ligase inhibitors as antibacterial drugs ESSENTIAL THERAPEUTICS, INC. 2003-06-26 US disclosed
WO-2003002063-A2 STRUCTURE-BASED DRUG DESIGN METHODS FOR IDENTIFYING D-ALA-D-ALA LIGASE INHIBITORS AS ANTIBACTERIAL DRUGS ESSENTIAL THERAPEUTICS, INC. (US) 2003-01-09 WO disclosed